NNZ-2566

I deleted Neuren’s NNZ-2566 from phase 1 as the Neuren website makes no mention of MS trials, and they say:

Neuren’s strategy is to undertake clinical trials for acute conditions, which are generally shorter and less expensive than those for chronic conditions. This strategy provides the most cost-effective means of increasing shareholder value while controlling risk.

Neuren decides which targets to pursue and which compounds to develop only after consideration of the cost and complexity of trials, the ease with which results can be validated, and assessment of market need and commercial opportunity.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: